Vimarsana
Biggest News Aggregation in the World

Page 5 - Nasdaq Caba News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Caba. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Caba Today - Breaking & Trending Today

Cabaletta Bio, Inc. (NASDAQ:CABA) Sees Significant Decline in Short Interest - Vimarsana News

Cabaletta Bio, Inc. (NASDAQ:CABA) Sees Significant Decline in Short Interest

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 3,260,000 shares, a drop of 39.2% from the August 15th total of 5,360,000 shares. Based on an average trading volume of 546,200 shares, the days-to-cover ratio […]

Cabaletta Bio (NASDAQ:CABA) Stock Price Up 7.9% - Vimarsana News

Cabaletta Bio (NASDAQ:CABA) Stock Price Up 7.9%

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) rose 7.9% during mid-day trading on Monday . The stock traded as high as $15.02 and last traded at $14.95. Approximately 78,930 shares traded hands during trading, a decline of 84% from the average daily volume of 483,739 shares. The stock had previously closed at $13.86. Analysts […]

Commodore Capital LP Has $15.18 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Vimarsana News

Commodore Capital LP Has $15.18 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Commodore Capital LP grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 81.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,835,000 shares of the company’s stock after acquiring an additional 824,641 shares during the quarter. Cabaletta […]

Cabaletta Bio (NASDAQ:CABA) Research Coverage Started at Citigroup - Vimarsana News

Cabaletta Bio (NASDAQ:CABA) Research Coverage Started at Citigroup

Citigroup assumed coverage on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research report sent to investors on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $22.00 price objective on the stock. Several other equities research analysts also recently issued reports on the company. HC Wainwright upped their price target […]

Source: wkrb13.com
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at Guggenheim - Vimarsana News

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research note released on Monday morning, Benzinga reports. Guggenheim currently has a $34.00 price objective on the stock. Separately, HC Wainwright raised their price target on Cabaletta Bio from $15.00 to $17.00 and gave the company a buy rating […]

Source: wkrb13.com